Heer Medical Undertakes the Launch of Gansu Province's 500,000-Case Cervical Cancer Screening Project

On May 4, 2018, the 2018 Gansu Province Rural Women's "Two Cancers" Screening Project was officially launched. Wuhan Heer Medical Technology Development Co., Ltd., a subsidiary of Boai Xinkaiyuan Medical Technology Group Co., Ltd. (Stock Code: 300109), undertook 500,000 cervical cancer screening cases under this project.

The launch ceremony was attended by more than 200 leaders and gynecologists from Gansu Province's maternal and child health system, including the President of the Gansu Maternal and Child Health Association, the Director of Gansu Province's Maternal and Child Health Department, directors of maternal and child health hospitals in eight prefecture-level cities of Gansu Province, and leaders from their respective health bureaus.

Heer Medical Chairman Mao Haizhan personally attended the launch ceremony and delivered a presentation on DNA detection technology to the assembled leaders and physicians. The event proceeded with great enthusiasm, receiving warm responses and strong support from all attending medical professionals.

In recent years, the incidence of cervical cancer and breast cancer among women in Gansu Province has been rising annually with a trend toward younger patients, severely threatening women's health and lives. The Gansu Province Women's Development Plan (2011–2020) set the goals of achieving "a routine screening rate of over 80% for common women's diseases" and "improving early diagnosis and treatment rates for cervical and breast cancer while reducing mortality" by 2020. Statistics show that in 2016, the routine examination rate for women's diseases in Gansu was 71.05%, with cervical cancer prevalence at 42.51 per 100,000 and breast cancer prevalence at 55.15 per 100,000 — both above the national average. The prevention and control situation is extremely serious, and the problem of women with "two cancers" falling into or returning to poverty due to illness is prominent. In response, Gansu Governor Tang Renjian emphasized at the Fifth Provincial Women's and Children's Work Conference last year: "If a woman in the family gets cancer and does not receive timely treatment, the family is essentially destroyed. Expanding the scope of 'two-cancer' screening and relief for women is very important — it is a good thing that spends small money, achieves great results, and benefits the long term." At the beginning of 2018, the Gansu provincial government included free "two-cancer" screenings for rural women throughout the province in the 2018 public welfare projects. The plan calls for an investment of 380 million RMB from 2018 to 2020 to provide free "two-cancer" screening for rural women aged 35 to 64 across the province — completing 25% of the target population in 2018, 35% in 2019, and 20% in 2020. Through "two-cancer" screening, the goal is to achieve "early prevention, early detection, early diagnosis, and early treatment," meeting the national targets for 2020. The aim is to continuously improve the disease prevention awareness and health standards of rural women throughout the province, effectively reduce the risk of poverty caused by illness, and fundamentally address the high incidence of "two cancers" among women.

As a leading integrated solution provider in China dedicated to early tumor diagnostics — offering diagnostic equipment, supporting software and reagents, technical support, personnel training, and equipment maintenance — Heer Medical, as the primary contractor for 500,000 cervical cancer screening cases in this project, will provide professional and caring health services to women across the region, enhancing their self-health awareness.

We wish Heer Medical's Gansu Province screening project every success!